Yaisa S. Andrews-Zwilling

Yaisa S. Andrews Zwilling PhD has a diverse work experience in the field of neuroscience and research.

Beginning in 2001, Yaisa completed their Ph.D. at the Max Planck Institute for Experimental Medicine, focusing on the assembly and function of active zones in neurotransmitter release at synapses.

Afterward, Yaisa worked as a Post Doctoral Fellow at the Max Planck Institute for Experimental Medicine from 2005 to 2006.

Yaisa then joined the Gladstone Institutes in 2007 as a Post Doctoral Fellow and later became a Research Scientist and Staff Research Scientist II. In this role, they collaborated with Dr. Robert Mahley and several Contract Research Organizations (CROs) to develop drugs that block the detrimental effects of apoE4 on nerve cells. Yaisa S. also served as the Co-Chair of the Gladstone Postdoctoral Advisory Committee (GPAC) where they demonstrated strong leadership skills by organizing and streamlining the committee's workflow and implementing new policies based on postdoc survey feedback.

In 2014, Yaisa joined SanBio as a Scientist III, leading a team of scientists and senior research associates in driving their pre-clinical program forward, focusing on stroke, traumatic brain injury, retinal degeneration, and Alzheimer's disease. In 2017, they took on the role of Associate Director of Research, responsible for pre-clinical development and research and development activities.

Yaisa also had a role as a Visiting Scholar at Stanford University from 2015 to 2016, where they led a collaborative research effort between SanBio Inc and Professor Mehrdad Shamloo's lab, focusing on establishing the mechanism of action of SanBio's cellular therapy product in rodent models of stroke and traumatic brain injury.

Starting in 2018, Yaisa joined Annexon Biosciences as Director of Research before being promoted to the role of Senior Director and Program Team Leader. Currently, they hold the position of VP, Global Program Team Leader, leading the company's efforts in developing disease-modifying therapeutics for neurological disorders such as Huntington's disease, Amyotrophic Lateral Sclerosis, and Alzheimer's disease. Yaisa S.'sresponsibilities at Annexon Biosciences include pre-clinical development, managing external collaborations, and overseeing research and development activities.

In addition to their research roles, Yaisa has also been an active board member of Jelani Girls Inc., a nonprofit organization, from 2016 to 2019.

Yaisa S. Andrews Zwilling PhD has a diverse education background. In 2016, they obtained a Certificate in Project Management from the Pharmaceutical Education and Research Institute. The same year, they attended Northwestern University - Kellogg School of Management for a program called Business for Scientists and Engineers.

Yaisa's main area of study is neuroscience. Yaisa S. pursued an M.Sc. and Ph.D. in Neuroscience at The University of Göttingen, Max Planck Research School. Additionally, they completed a Ph.D. in Neuroscience and an M.Sc. in Biochemistry and Chemistry at IMPRS-LS | International Max Planck Research School for Neuroscience, although the specific years are not provided.

For their undergraduate studies, Yaisa attended the University of the West Indies, St. Augustine Campus, where they earned a B.Sc. in Chemistry and Biochemistry.

There is no information available about Yaisa's education prior to university, as the details regarding their time at St. Joseph's Convent, St. Joseph, including the degree name and field of study, are not provided.